Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 [casopitant] and Intravenous Cyclophosphamide in Cancer Patients.

Next Previous
X
Search
Trial Profile

An Open Label, Repeat Dose, Randomized, Two Period Crossover Study to Investigate the Potential Pharmacokinetic Interactions Between Oral GW679769 [casopitant] and Intravenous Cyclophosphamide in Cancer Patients.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Casopitant (Primary) ; Cyclophosphamide
  • Indications Cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors GSK

    • Most Recent Events

    • 02 Jul 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 20 May 2009 Planned end date changed from 1 Oct 2008 to 1 Oct 2009 as reported by ClinicalTrials.gov.
    • 09 Oct 2008 Actual start date changed from August to March 2005, reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top